#1 Clinical Trials Search in Europe

Crofelemer

Crofelemer, a natural extract from the Croton lechleri tree, has been the subject of several clinical trials exploring its potential in treating various gastrointestinal conditions. These trials have focused on its efficacy in managing diarrhea associated with HIV/AIDS, irritable bowel syndrome (IBS), and even chemotherapy-induced diarrhea in cancer patients. The drug’s unique mechanism of action, which involves inhibiting chloride secretion in the intestines, has shown promise in reducing fluid loss and improving symptoms in patients with chronic diarrhea.

Table of Contents

What is Crofelemer?

Crofelemer is a medication derived from the red sap of the Croton lechleri tree, which grows in South America[1]. It is also known by its brand name Mytesi[2]. Crofelemer is primarily used to treat diarrhea associated with various medical conditions[3].

How Does Crofelemer Work?

Crofelemer works by reducing the secretion of chloride ions and fluid in the intestines[2]. It does this by blocking two types of chloride channels in the intestinal lining:

  • Cystic Fibrosis Transmembrane Conductance Regulator (CFTR): A protein that helps regulate the movement of salt and water in and out of cells.
  • Calcium-activated Chloride Channels (CaCC): Channels that allow chloride ions to pass through cell membranes in response to calcium signals.

By inhibiting these channels, Crofelemer helps reduce excessive fluid secretion in the intestines, which can help alleviate diarrhea[2].

Conditions Treated with Crofelemer

Crofelemer has been studied for use in several conditions that involve diarrhea:

  1. HIV-Associated Diarrhea: Crofelemer is FDA-approved for treating diarrhea in HIV/AIDS patients on antiretroviral therapy[4].
  2. Chemotherapy-Induced Diarrhea: Studies have investigated its use in preventing diarrhea in breast cancer patients undergoing chemotherapy[1].
  3. Irritable Bowel Syndrome with Diarrhea (IBS-D): Clinical trials have explored Crofelemer’s effectiveness in treating diarrhea-predominant IBS[5].
  4. Functional Diarrhea: Research has been conducted on Crofelemer’s potential in treating general cases of functional diarrhea[6].
  5. Short Bowel Syndrome (SBS): Studies are investigating Crofelemer’s potential in reducing ostomy output and improving quality of life in SBS patients[2].

How is Crofelemer Administered?

Crofelemer is typically taken orally in the form of tablets or powder. The dosage and frequency can vary depending on the condition being treated:

  • For HIV-associated diarrhea, the common dosage is 125 mg twice daily[4].
  • In clinical trials for other conditions, dosages have ranged from 125 mg to 500 mg twice daily[3].
  • For Short Bowel Syndrome, a powder form is being studied, administered three times daily[2].

It’s important to note that Crofelemer should be taken as prescribed by your healthcare provider.

Crofelemer in Clinical Trials

Crofelemer has been the subject of numerous clinical trials for various conditions:

  • A study (HALT-D) investigated its use in preventing diarrhea in breast cancer patients undergoing chemotherapy[1].
  • Multiple trials have explored its effectiveness in treating diarrhea-predominant IBS, particularly in women[5][7].
  • Research has been conducted on its potential in treating functional diarrhea[6].
  • An ongoing study is investigating its use in patients with Short Bowel Syndrome who have an ileostomy and require parenteral (intravenous) nutritional support[2].

Potential Side Effects

While specific side effects were not detailed in the provided clinical trial information, it’s important to note that all medications can have potential side effects. Crofelemer is generally considered to have minimal systemic absorption, which may limit serious adverse events[2]. However, as with any medication, patients should discuss potential side effects with their healthcare provider and report any unusual symptoms during treatment.

Aspect Details
Drug Name Crofelemer
Source Natural extract from Croton lechleri tree
Mechanism of Action Inhibits chloride secretion in intestines by blocking CFTR and CaCC channels
Conditions Studied HIV-associated diarrhea, IBS-D, Chemotherapy-induced diarrhea, Short Bowel Syndrome
Administration Oral tablets or powder, typically 125-500 mg twice daily
Primary Outcomes Reduction in diarrhea frequency, improved stool consistency, quality of life improvements
Safety Profile Minimal systemic absorption, generally well-tolerated
Notable Features Acts locally in intestines, does not affect gut motility, potential for various GI conditions

FAQ

  • What is Crofelemer and how does it work? Crofelemer is a natural extract from the Croton lechleri tree that works by inhibiting chloride secretion in the intestines. It blocks specific chloride channels, which helps reduce fluid loss and improve diarrhea symptoms without affecting gut motility or being absorbed systemically.
  • What conditions is Crofelemer being studied for in clinical trials? Crofelemer is being studied for various conditions including HIV-associated diarrhea, diarrhea-predominant irritable bowel syndrome (IBS-D), chemotherapy-induced diarrhea in cancer patients, and diarrhea in patients with short bowel syndrome.
  • How is Crofelemer administered in clinical trials? In most trials, Crofelemer is administered orally, either as tablets or as a powder for solution. The dosage and frequency vary depending on the study, but common doses range from 125 mg to 500 mg, taken twice daily.
  • What are some of the primary outcomes measured in Crofelemer clinical trials? Primary outcomes often include reduction in diarrhea frequency, changes in stool consistency (measured by scales like the Bristol Stool Form Scale), quality of life improvements, and safety assessments. Some trials also measure reductions in ostomy output or parenteral support needs in specific patient populations.
  • Are there any known side effects of Crofelemer based on clinical trials? While specific side effects are not detailed in the provided trial summaries, the studies consistently include safety assessments. Crofelemer is noted to have minimal systemic absorption, which may contribute to a favorable safety profile. However, as with any medication, potential side effects would be closely monitored and reported in the full trial results.

Ongoing Clinical Trials on Crofelemer

  • Study on Crofelemer for Adults with Short Bowel Syndrome and Intestinal Failure Without Colon in Continuity

    Recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Germany Italy

  • Study on the Safety and Effectiveness of Crofelemer for Children with Microvillus Inclusion Disease (MVID)

    Not recruiting

    1
    Investigated drugs:
    Italy

Glossary

  • Crofelemer: A natural extract from the Croton lechleri tree that inhibits chloride secretion in the intestines, used to treat various types of diarrhea.
  • HIV-associated diarrhea: Chronic diarrhea experienced by individuals with HIV/AIDS, often as a side effect of antiretroviral therapy or due to opportunistic infections.
  • Irritable Bowel Syndrome (IBS): A common digestive disorder characterized by abdominal pain, bloating, and altered bowel habits, including diarrhea or constipation.
  • Chemotherapy-induced diarrhea: Diarrhea that occurs as a side effect of cancer treatments, particularly chemotherapy.
  • Short Bowel Syndrome (SBS): A condition where the body cannot absorb enough nutrients due to a lack of functional small intestine, often resulting in chronic diarrhea and malnutrition.
  • Parenteral Support (PS): Nutrition provided through intravenous methods, bypassing the digestive system, often necessary for patients with severe digestive disorders.
  • Bristol Stool Form Scale: A diagnostic tool used to classify the form of human feces into seven categories, helping to assess bowel health and function.
  • CFTR: Cystic Fibrosis Transmembrane Conductance Regulator, a protein channel involved in chloride ion transport in cell membranes.
  • CaCC: Calcium-activated Chloride Channel, another type of chloride channel in cells that Crofelemer affects.
  • Ileostomy: A surgical opening in the abdominal wall that allows waste to leave the body when the colon or rectum is not functioning properly.

References

  1. https://clinicaltrials.gov/study/NCT02910219
  2. https://clinicaltrials.gov/study/NCT06326645
  3. https://clinicaltrials.gov/study/NCT00547898
  4. https://clinicaltrials.gov/study/NCT01374490
  5. https://clinicaltrials.gov/study/NCT00101725
  6. https://clinicaltrials.gov/study/NCT04486326
  7. https://clinicaltrials.gov/study/NCT00461526